Neurológia pre prax 4/2021

Siponimod: the first drug in secondary progressive multiple sclerosis in clinical practice

Siponimod is the first disease-modifying drug in the treatment of secondary progressive multiple sclerosis (SPRS). Its efficacy was demonstrated in the EXPAND trial. It is an oral selective sphingosine 1-phosphate receptor modulator, specifically of the 1 and 5 subtypes (S1P1, S1P5). Siponimod binds to the S1P1 receptors on lymphocytes, preventing their egress from lymph nodes, thus inhibiting their recirculation to the central nervous system (CNS). By crossing the blood-brain barrier, it affects the inflammatory and neurodegenerative processes occurring in the CNS during SPRS. A case report is used to show what treatment options for SPRS have been available so far and what siponimod can offer us and our patients.

Keywords: siponimod, secondary progressive multiple sclerosis, Expanded Disability Status Scale